Abstract：
The history of corneal cross-linking (CXL) dates back to 2003 when some German scientists investigated possible treatments to harden the corneal structure to increase its resistance in ectatic corneal diseases. Nowadays, CXL is considered the most effective therapy in ectatic corneal diseases due to its proven efficacy in hardening the cornea, thus halting the development of the disease. Since 2003, CXL applications have dramatically expanded and have been implemented in several other areas such as infectious keratitis, corneal edema, and before performing keratoplasty for various purposes. Moreover, several irradiation patterns are being studied to correct refractive errors, taking into account the corneal refractive changes that occur after the procedure. Currently, scleral cross-linking is also being investigated as a potential therapy in cases of progressive myopia and glaucoma. In this article, we provide a comprehensive overview of the available applications of cross-linking in nonectatic ocular conditions and highlight the possible future indications of this procedure.
摘要：
角膜交联（CXL）的历史可以追溯到2003年，当时一些德国科学家研究了可能的治疗方法，以硬化角膜结构以增加其在外生性角膜疾病中的抵抗力。如今,CXL被认为是最有效的治疗外生性角膜疾病，由于其在角膜硬化方面的有效性，从而阻止了疾病的发展。自2003年以来，CXL的应用已大大扩展，并已在其他几个领域实施，如感染性角膜炎，角膜水肿,在进行各种目的的角膜移植术之前。此外，正在研究几种辐射模式来校正屈光不正，考虑到手术后发生的角膜屈光变化。目前,巩膜交联也正在研究作为进行性近视和青光眼病例的潜在疗法。在这篇文章中,我们全面概述了交联在非扩张性眼部疾病中的现有应用,并重点介绍了该手术未来可能的适应症.
